Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Net Cash Flow (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Net Cash Flow for 7 consecutive years, with -$5.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Net Cash Flow rose 8.64% to -$5.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$3.8 million, a 88.47% increase, with the full-year FY2024 number at -$3.8 million, up 88.47% from a year prior.
  • Net Cash Flow was -$5.8 million for Q4 2024 at Actinium Pharmaceuticals, up from -$7.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $44.3 million in Q2 2022 to a low of -$14.4 million in Q1 2023.
  • A 4-year average of $576812.5 and a median of -$3.9 million in 2022 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 358.75% in 2022; the steepest drop was 3610.83% in 2022.
  • Actinium Pharmaceuticals' Net Cash Flow stood at -$4.3 million in 2021, then soared by 31.76% to -$2.9 million in 2022, then crashed by 117.1% to -$6.3 million in 2023, then increased by 8.64% to -$5.8 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Net Cash Flow are -$5.8 million (Q4 2024), -$7.4 million (Q3 2024), and $2.0 million (Q2 2024).